日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

  1. Home
  2. 抗體
  3. 科研級生物類似抗體
  4. TIGIT (Tiragolumab Biosimilar) Recombinant Monoclonal Antibody

TIGIT (Tiragolumab Biosimilar) Recombinant Monoclonal Antibody

  • 貨號：
    CSB-RA675446MB1HU
  • 規(guī)格：
    ￥83486
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    TIGIT (Tiragolumab Biosimilar Antibody)重組單克隆抗體是一種針對T細(xì)胞免疫球蛋白和ITIM結(jié)構(gòu)域蛋白（TIGIT）的科研用生物試劑。TIGIT作為重要的免疫檢查點(diǎn)分子，主要表達(dá)于活化的T細(xì)胞、自然殺傷（NK）細(xì)胞等免疫細(xì)胞表面，通過與配體CD155等結(jié)合，負(fù)向調(diào)控免疫細(xì)胞的激活與功能，在腫瘤免疫逃逸和自身免疫疾病中發(fā)揮關(guān)鍵作用。 該重組抗體通過基因工程技術(shù)制備，具有高特異性和親和力，能特異性識別并結(jié)合TIGIT分子，有效阻斷其免疫抑制信號通路。在科研應(yīng)用中，可用于體外細(xì)胞實(shí)驗(yàn)、動物模型研究等場景，助力探索TIGIT在免疫調(diào)節(jié)中的分子機(jī)制，包括對T細(xì)胞增殖、細(xì)胞因子分泌、NK細(xì)胞殺傷活性等功能的影響。此外，該抗體為開發(fā)針對TIGIT靶點(diǎn)的新型免疫治療策略提供了重要工具，可用于評估TIGIT阻斷在腫瘤、感染性疾病及自身免疫病等領(lǐng)域的潛在治療價值，支持相關(guān)基礎(chǔ)研究和藥物研發(fā)前期探索。 本產(chǎn)品僅用于實(shí)驗(yàn)室研究，不用于臨床診斷或治療用途。使用時需嚴(yán)格遵循相關(guān)實(shí)驗(yàn)規(guī)范，通過特異性結(jié)合實(shí)驗(yàn)驗(yàn)證其靶向性，確保實(shí)驗(yàn)結(jié)果的準(zhǔn)確性和可靠性。
  • Uniprot No.：
  • 基因名：
  • 別名：
    MTIG-7192A research-grade biosimilar; RG 6058 research-grade biosimilar; RG-6058 research-grade biosimilar; RO 7092284 research-grade biosimilar; RO-7092284 research-grade biosimilar; Tiragolumab research-grade biosimilar; Tiragolumab (genetical recombination) (JAN) research-grade biosimilar; Tiragolumab (USAN/INN) research-grade biosimilar ;TIGIT antibody; VSIG9 antibody; VSTM3 antibody; T-cell immunoreceptor with Ig and ITIM domains antibody; V-set and immunoglobulin domain-containing protein 9 antibody; V-set and transmembrane domain-containing protein 3 antibody
  • 反應(yīng)種屬：
    Human
  • 免疫原：
    Recombinant Human TIGIT protein
  • 免疫原種屬：
    Homo sapiens (Human)
  • 標(biāo)記方式：
    Non-conjugated
  • 克隆類型：
    Monoclonal
  • 濃度：
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液：
    0.01M PBS，pH7.4
  • 產(chǎn)品提供形式：
    Liquid
  • 應(yīng)用說明：
    Validation Status
    Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
    Guaranteed Quality
    ① Antibody purity?> 95% tested by SDS-PAGE.
    ② Endotoxin level < 0.1EU/ug tested by LAL method.
  • 儲存條件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期：
    3-4 weeks
  • 用途：
    It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

產(chǎn)品評價

靶點(diǎn)詳情

  • 功能：
    Binds with high affinity to the poliovirus receptor (PVR) which causes increased secretion of IL10 and decreased secretion of IL12B and suppresses T-cell activation by promoting the generation of mature immunoregulatory dendritic cells.
  • 基因功能參考文獻(xiàn)：
    1. The activation of PD-1 and TIGIT may exert negative regulatory effects and inhibit the immune response to cancer cells, resulting in immune escape of cancer cells. PMID: 30262800
    2. These findings highlight the importance of the TIGIT/CD226/PVR axis as an immune checkpoint barrier that could hinder future "cure" strategies requiring potent HIV-specific CD8(+) T cells PMID: 28084312
    3. High expression of TIGIT and Helios identifies CD4+ T cells with impaired immunological functions, primarily among patients with an advanced stage of Sezary syndrome. PMID: 27592800
    4. Natural killer cells and cytotoxic T cells express both TIGIT and DNAM-1 receptors, and in certain cases their effector functions are dictated by TIGIT or DNAM-1 signaling. Agonist and antagonist antibodies targeting either TIGIT or DNAM-1 present many therapeutic options for diseases spanning from cancer to auto-immunity. (Review) PMID: 28035916
    5. TIGIT contributes to functional T-cell impairment and associates with poor clinical outcome in acute myelogenous leukemia. The study suggests that blockade of TIGIT to restore T-cell function and antitumor immunity may represent a novel effective leukemia therapeutic. PMID: 26763253
    6. Blimp-1 binds to the promoters of PD-1 and TIGIT and positively regulates their expression in patients with acute myeloid leukemia. PMID: 28629373
    7. Data show that gastric cancer cells inhibit T-cell metabolism through CD155/TIGIT signaling. PMID: 28883004
    8. Our data provide important structural and biochemical determinants responsible for the recognition of nectin-2 by TIGIT. PMID: 27978489
    9. TIGIT is a powerful negative regulator of CD4(+) T cells in systemic lupus erythematosus. PMID: 28108989
    10. TIGIT signaling in NK cells after MDSC coculture led to a decrease in the phosphorylation of ZAP70/Syk and ERK1/2. PMID: 27503932
    11. energetic basis for the TIGIT/nectin-2 interaction and revealed that an "aromatic key" of nectin-2 is critical for this interaction, whereas variations in the lock were tolerated. PMID: 28515320
    12. TIGIT-positive circulating follicular helper T cells display robust B-cell help functions: potential role in sickle cell alloimmunization. PMID: 26250578
    13. implying that TIGIT exerts immunosuppressive effects by competing with DNAM-1 for the same ligand, CD155 PMID: 26842126
    14. These findings identify TIGIT as a novel marker of dysfunctional HIV-specific T cells PMID: 26741490
    15. This study shows that HBZ-induced TIGIT plays a pivotal role in attenuating host immune responses and shaping a microenvironment favorable to human T-cell leukemia virus type 1. PMID: 26735971
    16. a novel mechanism that links TIGIT expression with NK-cell functional heterogeneity, and this mechanism might partially explain why individuals have different susceptibilities to infection, autoimmune disease, and cancer. PMID: 26171588
    17. Human regulatory T cells expressing the receptors TIGIT and CD226 display widely divergent phenotypes in regard to expansion and activation. PMID: 25994968
    18. TIGIT and PD-1 blockade additively increased proliferation, cytokine production, and degranulation of tumor-antigen-specific CD8 T cells and CD8 TILs. TIGIT and PD-1 regulate the expansion and function of these T cells in melanoma. PMID: 25866972
    19. The results identify a bacterium-dependent, tumor-immune evasion mechanism in which tumors exploit the Fap2 protein of F. nucleatum to inhibit immune cell activity via TIGIT. PMID: 25680274
    20. Findings suggest that TIGIT is a key checkpoint inhibitor of chronic antiviral and antitumor responses through impairing CD226 function when disrupting its homodimerization. PMID: 25465800
    21. TIGIT/PVR ligation signaling mediates suppression of IFN-gamma production via the NF-kappaB pathway. PMID: 24817116
    22. TIGIT is phosphorylated at its cytoplasmic tail after its ligation with PVR. PMID: 23154388
    23. The Tim-3 pathway appears to control regulatory (Treg) and effector T cell balance via altering cell proliferation and apoptosis during hepatitis C virus infection. PMID: 22706088
    24. TIGIT can inhibit T cell functions by competing with CD226 and can also directly inhibit T cells in a T cell-intrinsic manner. PMID: 22427644
    25. data suggest a cis-trans receptor clustering mechanism for cell adhesion and signaling by the TIGIT/PVR complex and provide structural insights into how the PVR family of immunoregulators function PMID: 22421438
    26. that soluble Vstm3 attenuates T-cell responses in vitro and in vivo PMID: 21416464
    27. TIGIT exerts immunosuppressive effects by binding to poliovirus receptor and modulating cytokine production by dendritic cells. PMID: 19011627
    28. a novel immunoreceptor, Washington University Cell Adhesion Molecule, which is expressed on human follicular B helper T cells, was described. PMID: 19197944
    29. TIGIT counter inhibits the NK-mediated killing of tumor cells and protects normal cells from NK-mediated cytotoxicity thus providing an "alternative self" mechanism for MHC class I inhibition. PMID: 19815499

    顯示更多

    收起更多

  • 亞細(xì)胞定位：
    Cell membrane; Single-pass type I membrane protein.
  • 組織特異性：
    Expressed at low levels on peripheral memory and regulatory CD4+ T-cells and NK cells and is up-regulated following activation of these cells (at protein level).
  • 數(shù)據(jù)庫鏈接：

    HGNC: 26838

    OMIM: 612859

    KEGG: hsa:201633

    STRING: 9606.ENSP00000373167

    UniGene: Hs.421750



×
生命科學(xué)計算平臺